2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Sell | Sell | Buy | Neutral |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Buy | Neutral |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Buy | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 45.94 | 46.11 | 45.36 | -0.61 | -1.31% | 9.02M | NYSE | |||
| 94.18 | 94.61 | 92.38 | -0.59 | -0.62% | 11.47M | NYSE | |||
| 122.88 | 123.26 | 121.57 | +0.23 | +0.19% | 14.59M | NASDAQ | |||
| 45.45 | 45.60 | 44.78 | -0.81 | -1.75% | 1.86M | NYSE | |||
| 8.12 | 8.18 | 7.85 | -0.24 | -2.92% | 5.01M | NYSE | |||
| 3.53 | 3.55 | 3.47 | -0.070 | -1.94% | 11.29M | NYSE | |||
| 31.99 | 32.06 | 30.71 | -0.76 | -2.32% | 7.26M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 1.10 | 1.12 | 1.05 | 0.0000 | 0.00% | 157.34K | NYSE | |||
| 3.49 | 3.855 | 3.47 | -0.140 | -3.86% | 36.22M | NYSE | |||
| 1.16 | 1.19 | 1.15 | -0.0500 | -4.13% | 2.76M | NYSE | |||
| 49.75 | 50.06 | 49.38 | -0.36 | -0.72% | 15.75M | NYSE | |||
| 16.32 | 16.45 | 15.94 | +0.14 | +0.87% | 51.35M | NYSE | |||
| 205.88 | 206.11 | 203.29 | +0.99 | +0.48% | 1.61M | NYSE | |||
| 50.57 | 50.80 | 49.32 | -1.29 | -2.49% | 3.20M | NYSE |